更新于：2024-12-27

Ondansetron Hydrochloride

盐酸昂丹司琼

更新于：2024-12-27

概要

概要

基本信息

简介ZOFRAN®（盐酸昂丹司琼）是一种用于预防恶性肿瘤化疗和手术后恶心和呕吐的药物。ZOFRAN注射液的活性成分为盐酸昂丹司琼，其作用是选择性阻断5-HT3受体类型的血清素。这种作用机制可以通过阻断触发这些症状的大脑信号来有效地预防恶心和呕吐。ZOFRAN注射液是一种透明、无色、无热原、无菌的静脉用药溶液。它于1991年首次在美国由诺华制药公司批准上市。注射液的pH值范围为3.3至4.0。它是一种被广泛使用的药物，可以帮助癌症患者和进行手术的人控制症状，提高他们的生活质量。

药物类型

小分子化药

别名

Ondanseton Hydrochloride、ONDANSETRON、Ondansetron Hydrochloride and Glucose

+ [43]

靶点

5-HT3 receptor

作用机制

5-HT3 receptor拮抗剂(5-羟色胺受体3拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

University of CalgaryAspen Pharmacare Australia Pty Ltd.

+ [2]

非在研机构

Aquestive Therapeutics, Inc.Transcept Pharmaceuticals, Inc. (Old)山德士有限公司

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (1991-01-04),

化疗引起的恶心和呕吐术后恶心呕吐

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构

分子式C18H22ClN3O2

InChIKeyWRZJOBREMUDSSV-UHFFFAOYSA-N

CAS号103639-04-9

关联

655

项与盐酸昂丹司琼相关的临床试验

NCT05876585 / Not yet recruiting临床3期

A Randomized, Double-Blinded, Placebo-Controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis

A Randomized, Open-label, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of Ondansetron compared to Metoclopramide in the management of Nausea and Vomiting in Adult Patients with Acute Gastroenteritis.

开始日期2025-06-01

申办/合作机构

Adwia Pharmaceuticals Co.

NCT05844501 / Recruiting临床4期IIT

Inhibition of Small Conductance Calcium-Activated Potassium Current: A New Therapeutic Approach for Atrial Fibrillation

"Afib" is a common irregular heartbeat. Afib can cause stroke, blood clots, dementia and death. Medicines used to treat Afib often do not work well and can cause serious side effects. Clinicians need medicines that work better for Afib. Medicines for Afib work by blocking a current in the heart called a potassium current. There is a newer potassium current called IKas that can contribute to Afib. A medicine called ondansetron is used to keep people with cancer from getting sick to their stomach and throwing up. The investigators have found that ondansetron blocks IKas, and the investigators think that this means that ondansetron may work well to treat Afib. So, in this study the investigators want to find out if ondansetron can: 1) Reduce the amount of time that people have Afib, and 2) Slow down the heart rate when people have Afib. The investigators will study 80 people who are scheduled to have an AF ablation. Several weeks prior to undergoing the ablation procedure, these AF patients will be assigned by chance (like flipping a coin) to one of two groups: ondansetron 8 mg by mouth twice daily or a sugar pill (placebo), which they will take for 28 days. The people in the study will not know whether they are receiving ondansetron or placebo. The investigators will find out if ondansetron reduces the percentage of time that people are in Afib. Also, the investigators will find out if ondansetron slows the heart rate while people are having Afib. The investigators will compare the people in the study who take ondansetron with the people in the study who take placebo. This research will help the investigators to find out if ondansetron can be used as a medicine for people who have Afib.

开始日期2025-01-15

申办/合作机构

Indiana University

[+2]

NCT06747975 / Not yet recruiting临床4期IIT

Preventative Effect of Combining Dexamethasone with Ondansetron on Postoperative Nausea, Vomiting and Shivering in Children Undergoing Caudal Anesthesia

caudal epidural block is a technique used as an adjuvant to general anesthesia for postoperative analgesia in pediatric patients,especially those with infraumbilical, perineal and lower extremity surgery , because it reduces the need for perioperative and postoperative analgesia, reduces the need for general anesthesia, accelerates the awakening, suppresses the surgical neurohumoral stress response and can be performed easily The objective of the current study is to determine the efficacy and safety of prophylactic intravenous administration of combination of 0.1mg/kg of dexamethasone plus 4mg of ondansetron immediately before establishment of caudal block for prevention of Nausea&vomiting and Shivering in pediatric patients undergoing infra umbilical surgeries

开始日期2025-01-01

申办/合作机构

Assiut University

100 项与盐酸昂丹司琼相关的临床结果

登录后查看更多信息

100 项与盐酸昂丹司琼相关的转化医学

登录后查看更多信息

100 项与盐酸昂丹司琼相关的专利（医药）

登录后查看更多信息

5,117

项与盐酸昂丹司琼相关的文献（医药）

2025-01-01·ARCHIVES OF MICROBIOLOGY

Biopolymer-based oral films integrated with probiotic active compounds for improved health applications

Article

作者: Tunçer Çağlayan, Sinem

Orally dissolving films (ODFs) have emerged as a versatile platform that combines convenience, efficacy, and patient compliance. In this study, the cell-free supernatant of the oral probiotic Streptococcus salivarius M18 was incorporated into various biopolymer-based ODF formulations, evaluated for demolding, fragility, and flexibility. The combination of carboxymethyl cellulose, sodium alginate, and glycerol successfully formed stable films. The films were characterized by weight, thickness, pH, and disintegration times. Fourier-transform infrared spectroscopy (FTIR) was used to analyze ODF content and release profiles in simulated saliva. Unique absorption peaks in the cell-free product-incorporated ODF samples confirmed the integration of bacterial proteins, lipids, and nucleic acids into the ODF matrix. The biological activity of the ODF carrying M18 bioactive products was assessed by its inhibitory effect on the growth of Streptococcus mutans, a pathogen linked to dental plaque and cavities. Additionally, the anti-proliferative effect on cancer epithelial cells was demonstrated. This study show that probiotic products can be integrated into bio-based thin films without losing activity, making this delivery platform promising for local and potentially systemic effects.

2025-01-01·CLINICAL PHARMACOLOGY & THERAPEUTICS

Value of Pharmacogenetic Testing Assessed with Real‐World Drug Utilization and Genotype Data

Article

作者: Cajanus, Kristiina ; Sistonen, Johanna ; Lindstedt, Mats ; Tarkiainen, E. Katriina ; Kytö, Ville ; Khan, Sofia ; Falkenbach, Petra ; Orpana, Arto ; Korhonen, Mari ; Niemi, Mikko ; Turpeinen, Miia ; Perola, Markus ; Nyrönen, Tommi ; Kristiansson, Kati ; Ukkola‐Vuoti, Liisa ; Tornio, Aleksi ; Litonius, Kaisa ; Kulla, Noora

Implementation of pharmacogenetic testing in clinical care has been slow and with few exceptions is hindered by the lack of real‐world evidence on how to best target testing. In this retrospective register‐based study, we analyzed a nationwide cohort of 1,425,000 patients discharged from internal medicine or surgical wards and a cohort of 2,178 university hospital patients for purchases and prescriptions of pharmacogenetically actionable drugs. Pharmacogenetic variants were obtained from whole genome genotype data for a subset (n = 930) of the university hospital patients. We investigated factors associated with receiving pharmacogenetically actionable drugs and developed a literature‐based cost–benefit model for pre‐emptive pharmacogenetic panel testing. In a 2‐year follow‐up, 60.4% of the patients in the nationwide cohort purchased at least one pharmacogenetically actionable drug, most commonly ibuprofen (25.0%) and codeine (19.4%). Of the genotyped subset, 98.8% carried at least one actionable pharmacogenetic genotype and 23.3% had at least one actionable gene‐drug pair. Patients suffering from musculoskeletal or cardiovascular diseases were more prone to receive pharmacogenetically actionable drugs during inpatient episode. The cost–benefit model included frequently dispensed drugs in the university hospital cohort, comprising ondansetron (19.4%), simvastatin (7.4%), clopidogrel (5.0%), warfarin (5.1%), (es)citalopram (5.3%), and azathioprine (0.5%). For untargeted pre‐emptive pharmacogenetic testing of all university hospital patients, the model indicated saving €17.49 in direct healthcare system costs per patient in 2 years without accounting for the cost of the test itself. Therefore, it might be reasonable to target pre‐emptive pharmacogenetic testing to patient groups most likely to receive pharmacogenetically actionable drugs.

2025-01-01·Methods in molecular biology (Clifton, N.J.)

Proteogenomics for Non-model Ocean-Derived Fungi

Article

作者: Kumar, Abhishek

Most biological and biomedical experiments are designed and studied using the most common model organisms (MOs) like humans, mice, Escherichia coli, Saccharomyces cerevisiae, Neurospora crassa, worms, fruit flies, zebrafish, and Arabidopsis thaliana. These model organisms have been extensively studied and have a well-established set of genetic, physiological, and other tools available for research. In contrast, non-model organisms (NMOs) are those that are not traditionally used in scientific research and do not have a well-established set of genetic or other biological tools available for their study. The majority of MOs are associated with land habitats but rarely with ocean environments. The ocean forms the largest portion of our planet, yet ocean-derived organisms are the least explored, and these organisms are primarily NMOs. However, these are thrilling living entities, such as ocean-derived fungi (ODF). These ODFs are a diverse group of fungi that live in different ocean sectors, including the ocean, estuaries, and coastal ecosystems. These fungi are found to colonize and adapt to different substrates. They are important decomposers in marine ecosystems, breaking down dead organic matter and recycling nutrients. ODFs have adapted to survive in the unique and challenging conditions of the ocean environment, including high salt concentrations, low nutrient availability, and exposure to waves and currents. ODFs are potent producers of natural compounds with pharmaceutical and industrial applications, such as antibiotics, anticancer agents, antivirals, and enzymes for industrial processes. ODFs are an exciting group of fungi; however, these are the least studied because of the nonavailability of MOs from this group. Hence, there is a massive scope of expanding our current knowledge about ODFs, their genetic traits, potential future drug-producing capabilities, and lifestyle traits.With the advent of next-generation DNA sequencing, there is huge potential for the characterization of the genetic material of ODF as NMOs. Parallel proteomic methods also pose huge potential. A marriage of NGS and proteomic methods generates a new avenue called proteogenomics, which focuses on better annotation of existing genomic data. Both methods are getting cheaper and accessible to the research community for studying the proteogenomics of NMOs. Herein, the proteogenomic protocol development and data analyses are illustrated for the ocean-derived fungus Scopulariopsis brevicaulis.

253

项与盐酸昂丹司琼相关的新闻（医药）

2024-12-26

·丁香园

地塞米松不能随便用，这 15 个配伍禁忌需注意

（金牌讲师刘光辉老师教学⬆️）地塞米松能抑制白细胞、吞噬细胞在炎症部位的聚集，减轻组织对炎症的反应，在临床目前常用来抗炎、抗过敏，并且是危重疾病的急救药物。但国内外多项研究表明，地塞米松与很多药物配伍会产生不良反应，现总结如下，供各位参考。一、药物相互作用 1、与巴比妥类、苯妥英钠、利福平同时服用，地塞米松代谢促进作用减弱； 2、与利尿剂合用，会使血钾降低； 3、与碳酸酐酶抑制剂、两性霉素 B 合用，会加重低血钾； 4、与蛋白质同化激素合用，易产生痤疮； 5、与麻黄碱合用，会强化地塞米松效果； 6、与阿托品长期合用，会升高患者眼压； 7、可减弱抗凝药的作用，应注意调整剂量； 8、与水杨酸类药物合用，会增加水杨酸类药物的毒性，所以尽量避免，如果必须使用应酌情减量； 9、与维生素 A 作用相拮抗，应避免合用。二、相关配伍禁忌（点击可查看大图） -广告- 可的松、泼尼松、地塞米松......，13 种糖皮质激素你了解多少？ 🤔 可的松、泼尼松、地塞米松…有何区别？ ❓长效、中效、短效......等效剂量怎么换算？ 👊🏻 应用糖皮质激素，要警惕哪些不良反应？ ✅ 避免停药反应，具体怎么撤药？ 🔥 免费直播！为了帮助大家更好地掌握糖皮质激素的临床应用，丁香公开课特邀同济大学附属同济医院的刘光辉老师带来「糖皮质激素：临床应用与病例实战」全分享！糖皮质激素：临床应用与病例实战 ⏰ 12 月 26 日（周四）19:00 （扫码报名，免费观看👇）免费直播，还有「干货分享 + 奖品」👇 一、60 min 干货分享 ✔️超实用分享：搞定糖皮质激素用法和用量计算，盘点常见不良反应，「用药总结+病例实战」手把手教你搞定糖皮质激素！同济大学附属同济医院内分泌代谢科刘光辉老师分享宝贵临床经验。二、福利多多，直播间专属！ 🎁「值班必备：急症处理宝典」、「丁香园咖啡杯」免费抽~现场更有超多惊喜抽奖，助你搞定临床诊疗！（扫二维码报名，当天我们提醒您👇）（策划：夏夏）（题图：丁香公开课设计）参考资料： [1]王柳. 葡萄糖酸钙与地塞米松配伍禁忌[J]. 临床军医杂志,2011,39(6):1137. [2]祝金龙,冯锦强. 异丙嗪与地塞米松存在配伍禁忌[J]. 临床军医杂志,2011,39(5):891. [3]吴玲艳,叶雯. 氯化钙溴化钠注射液与地塞米松存在配伍禁忌[J]. 中华医院感染学杂志,2009,19(13):1764. [4]董玉兰,刘丽春,齐海燕. 盐酸溴己新注射液与庆大霉素、地塞米松存在配伍禁忌[J]. 中国实用护理杂志,2012,13(13):93-94. [5]陈洁彬,王芝珊. 谷氨酸诺氟沙星注射液与地塞米松磷酸钠存在配伍禁忌[J]. 中国误诊学杂志,2011,11(7):1742. [6]杨宝珍,蒋维连. 咪达唑仑注射液与地塞米松磷酸注射液存在配伍禁忌[J]. 中华现代护理杂志,2013,19(1):103. [7]马福颖,刘红艳,赵春艳. 甘露醇注射液与注射用地塞米松磷酸钠存在配伍禁忌1例[J]. 黑龙江医药科学,2012,35(6):42. [8]陈嘹. 长春西汀注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 中国实用护理杂志,2012,13(13):23. [9]苏鸽萍. 法莫替丁注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 中国实用护理杂志,2009,25(26):60. [10]俞霞. 盐酸托烷司琼注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 当代护士（中旬刊）,2015(2):189-189. [11]冀海锋,韩红维. 盐酸昂丹司琼与地塞米松磷酸钠、速尿注射液存在配伍禁忌[J]. 中国误诊学杂志,2009,9(2):483-483. [12]李永翠,毛勇,李莉. 甲磺酸罗哌卡因注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 中国实用护理杂志,2012,28(35):89. [13]王巧霞,李桂花,买晓琴,等. 地塞米松磷酸钠注射液与盐酸苯海拉明注射液存在配伍禁忌[J]. 中国实用护理杂志,2013,29(20):37. [14]曾竹. 低分子量肝素钙注射液与地塞米松磷酸钠注射液存在配伍禁忌[J]. 护理实践与研究,2016,13(13):72-72. [15]张楠,李芳. 葡萄糖酸依诺沙星与地塞米松存在配伍禁忌[J]. 中国民康医学,2008,20(6):598-598.

临床研究

2024-12-18

·Business Wire

Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board

BOSTON--( BUSINESS WIRE )--Valink Therapeutics, a biopharmaceutical company focused on discovering and developing innovative bispecific antibody-drug conjugates (bsADCs) to transform the treatment of cancer and other diseases, has appointed Martin D. Williams as Chair of its Board of Directors. The company also named its Scientific Advisory Board, which assembles experts in the discovery, development, manufacture and commercialization of ADCs and bispecific therapeutics. “ We are thrilled to welcome Martin, whose expertise in strategy, development and partnering, and track record of leading multiple U.S. biopharmaceutical companies, will be instrumental to the next stages of Valink. He brings deep experience advancing a wide range of therapeutics from early development through regulatory approval and commercialization and developing industry partnerships that move promising medicines closer to patients. Martin’s career journey, which began in the UK before his move to the U.S. over 30 years ago, mirrors Valink’s roots as a University of Oxford spinout based in the U.S., with a strong UK presence,” said Arne Scheu, DPhil, Co-founder and Chief Executive Officer of Valink. “ Furthermore, I am excited to announce our Scientific Advisory Board, which brings together a distinguished group of advisors who have been at the forefront of ADC and bispecific innovation and development.” Mr. Williams brings to Valink more than 35 years of experience in the global biopharmaceutical business, having closed more than $5 billion worth of corporate transactions, including numerous partnerships, M&A, and public and private financings. He recently served as Chief Executive Officer of Caraway Therapeutics, a venture-backed company developing therapeutics to modulate lysosomal function for neurodegenerative and rare diseases, through the company’s acquisition by Merck & Co. at the end of 2023. Previously, he was President and Chief Executive Officer of Tokai Pharmaceuticals, a clinical-stage oncology company; Chief Business Officer at Dicerna Pharmaceuticals, a leading RNAi company with programs in oncology; and Chief Business Officer and Senior Vice President for commercial and business development at Synta Pharmaceuticals, a clinical-stage public company focused on oncology and inflammation. Earlier in his career, he held various leadership positions and directed the development, commercialization and launch of several flagship brands for GSK, Hoffmann-La Roche and Lederle/Wyeth (now Pfizer), including GSK’s blockbusters Zantac® and Zofran®; Hoffmann La-Roche’s Xenical®; and Lederle/Wyeth’s global anti-infective portfolio, including Zosyn®/Tazocin®. He holds an MBA from Harvard Business School and an MS from the University of Manchester, UK. “ Valink has developed a compelling approach to realizing the unmet potential of ADCs to improve outcomes for patients with cancer and other diseases, which has been restricted by dose-limiting toxicities and the range of suitable targets. Their technology addresses a significant challenge to ADC innovation by enabling rapid and cost-effective generation and screening of bispecific ADCs, unlocking a vast range of target synergy and potentially bringing previously undruggable space within reach,” said Mr. Williams. “ I am excited to work closely with the Valink executive team and Board as the company builds on its discoveries and pursues its clinical aspirations.” Valink also announced the formation of its Scientific Advisory Board, initially consisting of: Sonia Quaratino, MD, PhD is Executive Vice President and Chief Medical Officer at Innate Pharma, a clinical-stage biotech utilizing monoclonal antibodies, multi-specific NK cell engagers and ADCs to develop immunotherapies for cancer. Her career spans over 25 years in basic research, clinical development and translational medicine across academia, biotech and global pharmaceuticals. She has held numerous leadership positions, including serving as CMO at Kymab (until its acquisition by Sanofi) and Georgiamune Inc, and was Professor of Immunology at the University of Southampton. Marc Damelin, PhD is Chief Scientific Officer at Alphina Therapeutics and an expert in oncology drug discovery and development. Previously he served as VP and Head of Biology at Mersana Therapeutics, a clinical-stage biotech developing ADCs to treat cancer. Prior to that he worked for a decade in ADC discovery and development in Pfizer's Oncology Research Unit. Robert Lutz, PhD , Chief Scientific Officer at leading ADC company Iksuda Therapeutics, is a recognized expert in ADC discovery and development. As VP of Translational R&D at ImmunoGen, he was responsible for bringing eight ADC product candidates into development and was the research lead for Kadcyla®, the first ADC to be approved for solid tumor indications. Antoine Awad , Principal Executive Officer of Synlogic, has extensive experience in CMC, bispecific drug development and partnerships. Prior to Synlogic, he held leadership positions at various biotechs, including Merrimack Pharmaceuticals, where he led CMC development, manufacturing and approval of ONIVYDE® for treatment of advanced pancreatic cancer and transitioned to Ipsen Bioscience to lead global commercial manufacturing of ONIVYDE®. Mihriban Tuna, PhD is Chief Executive Officer of Immutrin and Entrepreneur-in-Residence at Cambridge Innovation Capital, a leading UK-based venture company focused on deep tech and life sciences. She previously served as Chief Scientific Officer at Adaptate Biotherapeutics (acquired by Takeda) and SVP, Drug Discovery at F-star Therapeutics, and was an early employee at Domantis Ltd. (acquired by GSK). Alexey A. Lugovskoy, PhD is President and Chief Executive Officer of Diagonal Therapeutics, Entrepreneur-in-Residence at Atlas Ventures and Associate Editor of mAbs . He formerly served as Chief Operating Officer at Dragonfly, Chief Development Officer at Morphic, Vice President of Therapeutics at Merrimack Pharmaceuticals and Associate Director of Drug Discovery at Biogen. He joined Valink’s Board of Directors in 2023, and this additional appointment highlights a close collaboration between the Scientific Advisory Board, Board of Directors and leadership team. About Valink Therapeutics Valink Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of first-in-class bispecific antibody-drug conjugates (bsADCs) to transform the treatment of cancer and other diseases. Valink’s technology platform utilizes a modular assembly approach to rapidly generate bsADCs with therapeutic potential, testing drugs at unparalleled scale and speed to improve on the payload delivery and selectivity of conventional ADCs. The company is based in Boston, Massachusetts and has research and development operations in London, UK. For more information, visit the company’s website at www.valinktx.com or contact the company at connect@valinktx.com .

高管变更抗体药物偶联物并购上市批准

2024-12-15

·药筛

司来帕格片两首仿同时获批，伏诺拉生片 9家仿制药申请 | 仿制药周报（12.9-12.15）

统计每周仿制药一致性评价申报、上市申请（12.2-12.08） 1、仿制药上市申请获批药品名称企业名称分类受理号阿伐那非片扬州市三药制药有限公司3CYHS2400348氨溴特罗口服溶液海南天盛保和生物科技有限公司;安徽永生堂药业有限责任公司3CYHS2300746丙戊酸钠缓释片(Ⅰ)湖南省湘中制药有限公司4CYHS2302854布洛芬混悬液江苏万高药业股份有限公司4CYHS2302105布美他尼注射液杭州沐源生物医药科技有限公司;成都市海通药业有限公司3CYHS2301876单硝酸异山梨酯缓释片鲁南制药集团股份有限公司;鲁南贝特制药有限公司3CYHS2300926地拉罗司分散片石家庄四药有限公司4CYHS2302285碘普罗胺注射液杭州沐源生物医药科技有限公司;浙江莎普爱思药业股份有限公司4CYHS2302202二甲双胍恩格列净片(Ⅰ)浙江华海药业股份有限公司4CYHS2302731二甲双胍恩格列净片(Ⅰ)重庆希韦医药科技有限公司;重庆华森制药股份有限公司4CYHS2302606二甲双胍恩格列净片(Ⅵ)重庆希韦医药科技有限公司;重庆华森制药股份有限公司4CYHS2302607法莫替丁注射液江苏瑜兴医药科技有限公司;马鞍山丰原制药有限公司3CYHS2302215骨化三醇注射液南京海融制药有限公司4CYHS2302586骨化三醇注射液南京海融制药有限公司4CYHS2302587甲磺酸艾立布林注射液正大天晴药业集团股份有限公司4CYHS2302221卡铂注射液四川百利药业有限责任公司;成都百利多特生物药业有限责任公司4CYHS2302625利丙双卡因乳膏河北新张药股份有限公司;河北亚东制药有限公司4CYHS2300553利丙双卡因乳膏杭州领业医药科技有限公司4CYHS2300507利丙双卡因乳膏海南紫程众投生物科技有限公司;江西德成制药有限公司4CYHS2201788硫酸氨基葡萄糖胶囊海南斯达制药有限公司;海南赛立克药业有限公司4CYHS2302902硫酸氨基葡萄糖胶囊安徽省先锋制药有限公司4CYHS2301512硫酸镁钠钾口服用浓溶液浙江恒研医药科技有限公司;浙江赛默制药有限公司4CYHS2302015硫酸镁钠钾口服用浓溶液重庆健能医药开发有限公司;浙江赛默制药有限公司4CYHS2301751硫酸镁注射液金陵药业股份有限公司南京金陵制药厂3CYHS2301554罗库溴铵注射液华中药业股份有限公司4CYHS2301679罗库溴铵注射液华中药业股份有限公司4CYHS2301680洛度沙胺氨丁三醇滴眼液武汉先路医药科技股份有限公司;四川禾亿制药有限公司3CYHS2200415门冬氨酸钾注射液山东华鲁制药有限公司3CYHS2301622生理氯化钠溶液吉林省都邦药业股份有限公司3CYHS2300148司来帕格片杭州朱养心药业有限公司4CYHS2301457司来帕格片杭州朱养心药业有限公司4CYHS2301459司来帕格片杭州朱养心药业有限公司4CYHS2301458司来帕格片常州恒邦药业有限公司;江苏豪森药业集团有限公司4CYHS2101338司来帕格片常州恒邦药业有限公司;江苏豪森药业集团有限公司4CYHS2101337碳酸镧咀嚼片Natco Pharma Limited5.2JXHS2000107碳酸镧咀嚼片Natco Pharma Limited5.2JXHS2000108头孢泊肟酯片国药集团致君（深圳）制药有限公司4CYHS2302800西甲硅油乳剂山东新鲁医药科技有限公司;浙江赛默制药有限公司4CYHS2301364小儿法罗培南钠颗粒济川药业集团有限公司4CYHS2301479缬沙坦氨氯地平片(Ⅰ)湖北午时药业股份有限公司4CYHS2301728盐酸丙卡特罗口服溶液广东稳健药业有限公司;山西同达药业有限公司3CYHS2301636盐酸丙卡特罗口服溶液广东稳健药业有限公司;山西同达药业有限公司3CYHS2301635盐酸达泊西汀片武汉华尔生物科技有限公司;宁夏康亚药业股份有限公司4CYHS2301919盐酸多巴胺注射液仁合益康集团有限公司;河北仁合益康药业有限公司3CYHS2301335盐酸去氧肾上腺素注射液山东威智百科药业有限公司3CYHS2301113盐酸去氧肾上腺素注射液广州维奥康药业科技有限公司;广东星昊药业有限公司3CYHS2300680盐酸乌拉地尔注射液吉林四长制药有限公司4CYHS2302294盐酸乌拉地尔注射液山西德元堂药业有限公司4CYHS2302188盐酸乌拉地尔注射液山西德元堂药业有限公司4CYHS2302189依托咪酯中/长链脂肪乳注射液宜昌人福药业有限责任公司4CYHS2301866注射用氯诺昔康浙江佰奥医药科技有限公司;湖北潜江制药股份有限公司4CYHS2302345注射用头孢他啶阿维巴坦钠苏州二叶制药有限公司;齐鲁安替制药有限公司4CYHS2301942左炔诺孕酮片EXELTIS HEALTHCARE S.L.5.2JYHS2300010左氧氟沙星氯化钠注射液石药银湖制药有限公司4CYHS2301924 注：灰色字体部分受理号结论为不批准。 2、一致性评补充申请获批药品名称企业名称受理号氨甲环酸氯化钠注射液成都倍特药业股份有限公司;四川太平洋药业有限责任公司CYHB2450269倍他米松磷酸钠注射液武汉天安医药科技有限公司;天津金耀药业有限公司CYHB2350614倍他米松磷酸钠注射液武汉天安医药科技有限公司;天津金耀药业有限公司CYHB2350615呋塞米注射液石药银湖制药有限公司CYHB2350761呋塞米注射液石药集团欧意药业有限公司CYHB2350713枸橼酸西地那非片成都地奥制药集团有限公司;地奥集团成都药业股份有限公司CYHB2350937枸橼酸西地那非片成都地奥制药集团有限公司;地奥集团成都药业股份有限公司CYHB2350936甲硝唑氯化钠注射液湖南康源制药有限公司CYHB2450088氯化钾注射液遂成药业股份有限公司CYHB2450231氯化钾注射液遂成药业股份有限公司CYHB2450230硝苯地平缓释片(Ⅱ)乐声药业石家庄有限公司CYHB2450096盐酸布比卡因注射液湖南科伦制药有限公司CYHB2450058盐酸氟桂利嗪胶囊迪沙药业集团有限公司CYHB2350877伊班膦酸钠注射液天津红日药业股份有限公司;哈尔滨三联药业股份有限公司CYHB2350898伊班膦酸钠注射液天津红日药业股份有限公司;哈尔滨三联药业股份有限公司CYHB2350899注射用头孢唑肟钠广州白云山天心制药股份有限公司CYHB2350912注射用头孢唑肟钠广州白云山天心制药股份有限公司CYHB2350911 注：灰色字体部分受理号结论为不批准。 3、新增仿制药上市申请药品名称企业名称分类受理号阿昔莫司胶囊海南药谷云生物科技有限公司;江苏诚康药业有限公司4CYHS2404273艾地骨化醇软胶囊北京斯利安药业有限公司4CYHS2404255昂丹司琼口腔溶解薄膜上海上药中西制药有限公司3CYHS2404325昂丹司琼口腔溶解薄膜上海上药中西制药有限公司3CYHS2404324比拉斯汀片宁波美诺华天康药业有限公司4CYHS2404304比索洛尔氨氯地平片上海衡山药业有限公司4CYHS2404263丙戊酸钠缓释片(Ⅰ)华益药业科技（安徽）有限公司4CYHS2404332丙戊酸钠缓释片(Ⅰ)浙江普洛康裕制药有限公司4CYHS2404274布比卡因脂质体注射液浙江圣兆药物科技股份有限公司;杭州澳亚生物技术股份有限公司3CYHS2404308布比卡因脂质体注射液浙江圣兆药物科技股份有限公司;杭州澳亚生物技术股份有限公司3CYHS2404307布美他尼注射液绪必迪药业（沧州）有限公司;河北凯威制药有限责任公司3CYHS2404331布南色林片合肥英太制药有限公司4CYHS2404318布瑞哌唑片M/s MSN LABORATORIES PRIVATE LIMITED5.2JYHS2400062布瑞哌唑片M/s MSN LABORATORIES PRIVATE LIMITED5.2JYHS2400064布瑞哌唑片M/s MSN LABORATORIES PRIVATE LIMITED5.2JYHS2400063布瑞哌唑片M/s MSN LABORATORIES PRIVATE LIMITED5.2JYHS2400061醋酸兰瑞肽缓释注射液(预充式)四川汇宇制药股份有限公司4CYHS2404311醋酸兰瑞肽缓释注射液(预充式)四川汇宇制药股份有限公司4CYHS2404309醋酸兰瑞肽缓释注射液(预充式)四川汇宇制药股份有限公司4CYHS2404310单硝酸异山梨酯缓释片南京华兴医药科技有限公司;湖北荆江源制药股份有限公司4CYHS2404283恩格列净片山东益康药业股份有限公司4CYHS2404305恩格列净片山东益康药业股份有限公司4CYHS2404306二甲双胍恩格列净片(Ⅰ)河北龙海药业有限公司4CYHS2404299二甲双胍恩格列净片(Ⅴ)河北龙海药业有限公司4CYHS2404298二甲双胍恩格列净片(Ⅵ)河北龙海药业有限公司4CYHS2404297二十碳五烯酸乙酯软胶囊甘正（海南）生物药业有限公司;浙江维康药业股份有限公司4CYHS2404317法莫替丁注射液杭州民生药物研究院有限公司;杭州民生药业股份有限公司3CYHS2404291夫西地酸乳膏江苏盈科生物制药有限公司4CYHS2404259氟伐他汀钠缓释片浙江普洛康裕制药有限公司4CYHS2404326复方聚乙二醇电解质散（II）湖南普道医药技术有限公司;湖南九典制药股份有限公司3CYHS2404347复方聚乙二醇电解质散(III)江西亿友药业有限公司4CYHS2404258复合磷酸氢钾注射液石家庄荣雾迪医药科技有限公司;山西诺成制药有限公司3CYHS2404290富马酸伏诺拉生片四川迪菲特药业有限公司4CYHS2404282富马酸伏诺拉生片海南广升誉制药有限公司;江苏诚康药业有限公司4CYHS2404292富马酸伏诺拉生片国大（吉林）制药集团有限公司;天津汉瑞药业有限公司4CYHS2404286富马酸伏诺拉生片国大（吉林）制药集团有限公司;天津汉瑞药业有限公司4CYHS2404285富马酸伏诺拉生片四川迪菲特药业有限公司4CYHS2404281富马酸伏诺拉生片海南广升誉制药有限公司;江苏诚康药业有限公司4CYHS2404293富马酸伏诺拉生片山东鲁抗医药股份有限公司4CYHS2404264富马酸伏诺拉生片陕西西岳制药有限公司4CYHS2404271富马酸伏诺拉生片云鹏医药集团有限公司4CYHS2404267富马酸伏诺拉生片陕西西岳制药有限公司4CYHS2404272富马酸伏诺拉生片云鹏医药集团有限公司4CYHS2404268富马酸伏诺拉生片山东鲁抗医药股份有限公司4CYHS2404265富马酸伏诺拉生片北京北陆药业股份有限公司4CYHS2404253富马酸伏诺拉生片北京北陆药业股份有限公司4CYHS2404252富马酸依美斯汀滴眼液石家庄四药有限公司4CYHS2404335钆喷酸葡胺注射液重庆圣华曦药业股份有限公司4CYHS2404333琥珀酸亚铁片赤峰固得药业有限公司;浙江诺得药业有限公司3CYHS2404279己酮可可碱缓释片杭州康恩贝制药有限公司3CYHS2404350甲泼尼龙片上海理想制药有限公司;江苏鹏鹞药业有限公司4CYHS2404287克立硼罗软膏浙江百代医药科技有限公司;浙江赛默制药有限公司4CYHS2404296利伐沙班口崩片北京福元医药股份有限公司3CYHS2404327利伐沙班口崩片北京福元医药股份有限公司3CYHS2404328利格列汀二甲双胍片(Ⅰ)北京百奥药业有限责任公司4CYHS2404261磷酸特地唑胺片浙江东亚药业股份有限公司4CYHS2404355硫酸阿托品注射液江苏润恒制药有限公司3CYHS2404301硫酸氨基葡萄糖胶囊湖南诺纳医药科技有限公司;湖南九典制药股份有限公司4CYHS2404351硫酸镁钠钾口服用浓溶液湖北唯森制药有限公司4CYHS2404358罗沙司他胶囊浙江高跖医药科技股份有限公司;宁波美诺华天康药业有限公司4CYHS2404321罗沙司他胶囊浙江高跖医药科技股份有限公司;宁波美诺华天康药业有限公司4CYHS2404320马来酸阿伐曲泊帕片江苏吴中医药集团有限公司苏州制药厂4CYHS2404302门冬氨酸钾注射液海南慧通生物医药科技有限公司;山东北大高科华泰制药有限公司3CYHS2404277门冬氨酸钾注射液海南慧通生物医药科技有限公司;山东北大高科华泰制药有限公司3CYHS2404276咪达唑仑口服溶液成都倍特药业股份有限公司3CYHS2404337米拉贝隆缓释片浙江普利药业有限公司4CYHS2404323莫匹罗星软膏华润三九医药股份有限公司;广东华润顺峰药业有限公司4CYHS2404254钠钾镁钙注射用浓溶液苏州朗易生物医药研究有限公司;江西东抚制药有限公司3CYHS2404289帕拉米韦注射液嘉亨（珠海横琴）医药科技有限公司;广东星昊药业有限公司3CYHS2404329培哚普利氨氯地平片(Ⅰ)杭州和泽坤元药业有限公司;山西同达药业有限公司4CYHS2404330苹果酸奈诺沙星氯化钠注射液贵州科伦药业有限公司4CYHS2404357瑞舒伐他汀依折麦布片（I）江苏德源药业股份有限公司4CYHS2404345瑞舒伐他汀依折麦布片（I）成都倍特药业股份有限公司4CYHS2404344噻托溴铵吸入喷雾剂天津信达制药有限公司4CYHS2404343双氯芬酸二乙胺乳胶剂丽彩甘肃西峰制药有限公司4CYHS2404295双氯芬酸二乙胺乳胶剂丽彩甘肃西峰制药有限公司4CYHS2404294双氯芬酸钠缓释片四川依科制药有限公司4CYHS2404346碳酸氢钠注射液江苏宝东医药科技有限公司;江苏大红鹰恒顺药业有限公司3CYHS2404303头孢泊肟酯干混悬剂石家庄四药有限公司3CYHS2404352维生素B12注射液海南元盈医药科技有限公司;酒泉大得利制药股份有限公司3CYHS2404312乌帕替尼缓释片重庆华邦制药有限公司4CYHS2404275乌帕替尼缓释片山东齐都药业有限公司4CYHS2404262吸入用乙酰半胱氨酸溶液山西普恒制药有限公司4CYHS2404284西格列汀二甲双胍缓释片南京易亨制药有限公司3CYHS2404322腺苷钴胺胶囊南京海纳制药有限公司3CYHS2404316腺苷注射液广州大光制药有限公司;广东星昊药业有限公司4CYHS2404334小儿复方氨基酸注射液(19AA-Ⅰ)武汉久安药物研究院有限公司;四川科伦药业股份有限公司3CYHS2404359溴芬酸钠滴眼液江西马应龙美康药业有限公司;浙江尖峰药业有限公司4CYHS2404356盐酸埃克替尼片昆山龙灯瑞迪制药有限公司4CYHS2404280盐酸氨溴索口服溶液海南斯达制药有限公司4CYHS2404338盐酸氨溴索口服溶液海南斯达制药有限公司4CYHS2404339盐酸氨溴索口服溶液海南斯达制药有限公司4CYHS2404340盐酸氨溴索口服溶液海南斯达制药有限公司4CYHS2404341盐酸氨溴索口服溶液海南斯达制药有限公司4CYHS2404342盐酸达泊西汀片云南龙津康佑生物医药有限公司;昆明龙津药业股份有限公司4CYHS2404349盐酸达泊西汀片云南龙津康佑生物医药有限公司;昆明龙津药业股份有限公司4CYHS2404348盐酸伐地那非片浙江诺得药业有限公司4CYHS2404266盐酸克林霉素棕榈酸酯颗粒广州大光制药有限公司;湖北唯森制药有限公司3CYHS2404260盐酸利多卡因凝胶华润双鹤药业股份有限公司;华润紫竹药业有限公司3CYHS2404314盐酸氯胺酮注射液国药集团工业有限公司廊坊分公司3CYHS2404278盐酸纳洛酮注射液海南葫芦娃药业集团股份有限公司3CYHS2404336盐酸纳美芬注射液南京正科医药股份有限公司3CYHS2404257盐酸普萘洛尔片石家庄龙泽制药股份有限公司3CYHS2404319依折麦布阿托伐他汀钙片南京海纳医药科技股份有限公司;南京海纳制药有限公司4CYHS2404270依折麦布阿托伐他汀钙片南京海纳医药科技股份有限公司;南京海纳制药有限公司4CYHS2404269依折麦布片华润赛科药业有限责任公司4CYHS2404315脂肪乳氨基酸(17)葡萄糖(19%)注射液辽宁海思科制药有限公司4CYHS2404354注射用硫酸艾沙康唑上药东英（江苏）药业有限公司;博瑞制药（苏州）有限公司4CYHS2404300注射用乳糖酸红霉素广州艾奇西新药研究有限公司;成都通德药业有限公司3CYHS2404313注射用替考拉宁丽珠集团丽珠制药厂4CYHS2404288左乙拉西坦口服溶液广东合威制药有限公司4CYHS2404353唑来膦酸注射液浙江康吉尔药业有限公司3CYHS2404256 4、新增一致性评价补充申报药品名称企业名称受理号诺氟沙星胶囊哈药集团制药总厂;哈药集团制药六厂CYHB2450612碳酸氢钠注射液山东华鲁制药有限公司CYHB2450610碳酸氢钠注射液山东华鲁制药有限公司CYHB2450609维生素B6注射液山东辉成药业有限公司CYHB2450611盐酸昂丹司琼注射液辰欣药业股份有限公司CYHB2450605盐酸昂丹司琼注射液辰欣药业股份有限公司CYHB2450604盐酸甲氧氯普胺注射液遂成药业股份有限公司CYHB2450608盐酸索他洛尔片常州制药厂有限公司CYHB2450607盐酸乙胺丁醇片蚌埠丰原涂山制药有限公司CYHB2450606注射用阿奇霉素瑞阳制药股份有限公司CYHB2450601注射用阿奇霉素瑞阳制药股份有限公司CYHB2450600注射用苯唑西林钠山西振东泰盛制药有限公司CYHB2450602注射用苯唑西林钠山西振东泰盛制药有限公司CYHB2450603 数据来源：摩熵医药用摩熵药筛小程序，随时随地查周报

一致性评价上市批准

100 项与盐酸昂丹司琼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00678	盐酸昂丹司琼	A04AA01	DB00904

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
恶心	中国	福安药业（集团）股份有限公司	1996-01-01
呕吐	中国	福安药业（集团）股份有限公司	1996-01-01
放疗引起的恶心和呕吐	澳大利亚	Aspen Pharmacare Australia Pty Ltd.	1991-04-17
化疗引起的恶心和呕吐	美国	Sandoz, Inc.	1991-01-04
术后恶心呕吐	美国	Sandoz, Inc.	1991-01-04

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晕厥	临床3期	加拿大	University of Calgary	2024-12-01
酒精使用障碍	临床3期	保加利亚	Adial Pharmaceuticals, Inc.	2020-02-01
酒精使用障碍	临床3期	克罗地亚	Adial Pharmaceuticals, Inc.	2020-02-01
酒精使用障碍	临床3期	爱沙尼亚	Adial Pharmaceuticals, Inc.	2020-02-01
酒精使用障碍	临床3期	芬兰	Adial Pharmaceuticals, Inc.	2020-02-01
酒精使用障碍	临床3期	拉脱维亚	Adial Pharmaceuticals, Inc.	2020-02-01
酒精使用障碍	临床3期	波兰	Adial Pharmaceuticals, Inc.	2020-02-01
酒精使用障碍	临床3期	瑞典	Adial Pharmaceuticals, Inc.	2020-02-01
急性胃肠炎	临床3期	加拿大	University of Calgary	2019-09-04
腹泻	临床3期	加拿大	University of Calgary	2019-09-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


UEGW	N/A	腹泻	-	Ondansetron 4mg	觸淵繭鹽膚蓋鹽鹽廠艱(鏇衊膚壓鹽觸繭願顧夢) = Adverse events were significantly higher in non-responders compared to responders (p=0.02) 廠鹹顧積繭製衊鑰製顧 (築醖膚鑰艱鏇糧艱顧齋 ) 更多	-	2024-10-13
ASCO2024	N/A	-	-	ondansetron (Medicare Part D Prescription Drug Plans (PDPs))	壓艱鹽獵餘鹽遞膚鬱鏇(鏇網淵範獵餘選構網蓋) = 鑰鑰齋壓餘艱顧鹹獵鹹簾鑰憲選製廠觸構衊淵 (繭鹹獵構觸鏇顧簾鑰憲 ) 更多	-	2024-05-24
				ondansetron (Medicare Advantage plans (MADPs))	壓艱鹽獵餘鹽遞膚鬱鏇(鏇網淵範獵餘選構網蓋) = 觸淵艱築獵觸夢繭壓廠簾鑰憲選製廠觸構衊淵 (繭鹹獵構觸鏇顧簾鑰憲 ) 更多
NCT03435003 (CTgov)	临床4期	术后恶心呕吐 \| 呕吐	83	dexmedetomidine+Compazine+Total intravenous anesthesia+scopolamine transdermal+sugammadex+Reglan+Propofol+Fentanyl+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm)	繭壓鬱鑰願鹽鏇醖繭廠(鹽憲築鑰糧網憲憲鬱糧) = 繭憲窪鏇積選選觸選糧願範鹽顧壓衊襯選鏇餘 (齋鏇顧膚觸鏇鹽憲夢醖, 範遞膚齋淵鹽糧繭衊糧 ~ 觸窪願膚壓願鏇簾顧獵) 更多	-	2024-02-14
				Compazine+sugammadex+Reglan+Sevoflurane+Desflurane+Ondansetron+Dexamethasone (Control Arm)	繭壓鬱鑰願鹽鏇醖繭廠(鹽憲築鑰糧網憲憲鬱糧) = 顧蓋願製糧淵積鹹鑰鹹願範鹽顧壓衊襯選鏇餘 (齋鏇顧膚觸鏇鹽憲夢醖, 窪襯壓襯網範範夢餘獵 ~ 齋膚顧襯繭衊網餘夢製) 更多
NCT05098067 (CTgov)	临床2期	妊娠剧吐 \| 恶心 \| 妊娠呕吐	30	Lactated Ringers, Intravenous+Metoclopramide+Capsaicin Topical Cream+Ondansetron (Intervention Group)	鹽憲簾壓觸餘淵顧鑰醖(衊糧範壓膚觸鏇範蓋鹽) = 鹹簾鬱淵醖蓋艱淵夢製夢顧壓廠淵鬱夢積襯鏇 (簾獵鹽衊艱願築膚選選, 獵餘選廠構鬱壓鬱廠遞 ~ 遞憲糧範衊鬱膚夢鬱餘) 更多	-	2024-02-07
				Lactated Ringers, Intravenous+Metoclopramide+Ondansetron (Placebo Group)	鹽憲簾壓觸餘淵顧鑰醖(衊糧範壓膚觸鏇範蓋鹽) = 積糧鑰築衊鏇範餘製繭夢顧壓廠淵鬱夢積襯鏇 (簾獵鹽衊艱願築膚選選, 艱築鏇選醖顧選觸鹹鏇 ~ 鏇襯齋製網遞壓鹹糧壓) 更多
Pubmed \| Int J Surg	N/A	低血压	-	Ondansetron 0.1 mg/kg	淵糧繭築艱積獵鬱醖鑰(構觸顧蓋繭餘壓鏇觸願) = 繭構選鹽膚獵製顧網憲鑰願選繭齋選觸繭憲遞 (淵艱蓋簾鑰繭顧齋壓顧, 0.013 ~ 0.029) 更多	积极	2024-02-01
				Saline Control	淵糧繭築艱積獵鬱醖鑰(構觸顧蓋繭餘壓鏇觸願) = 憲壓製遞糧顧醖積遞膚鑰願選繭齋選觸繭憲遞 (淵艱蓋簾鑰繭顧齋壓顧, 0.024 ~ 0.043) 更多
NCT03237611 (CTgov)	临床2期	化疗引起的恶心和呕吐	15	Ondansetron 16 MG+Aprepitant 125 mg+Dexamethasone+Fosaprepitant 115 MG	糧餘衊鏇鹽積顧艱衊壓(網遞繭衊憲鹽構餘鏇築) = 窪襯鏇築鑰觸鬱簾襯遞製築鏇製獵製鏇顧製鏇 (蓋糧壓鹹範鹹遞餘鹹壓, 鹽鏇壓觸膚遞觸鹽艱顧 ~ 齋製鑰築壓憲糧積窪築) 更多	-	2023-11-13
NCT02991456 (CTgov)	临床2期	放疗引起的恶心和呕吐 \| 胶质瘤	48	Ondansetron+Rolapitant (Sequence A)	選窪淵衊鹽齋醖鏇衊鹹(膚淵襯選憲襯窪蓋積餘) = 膚願鏇選範觸齋網製鏇壓齋遞繭憲製願網壓淵 (繭鬱艱膚廠憲蓋鏇衊鹽, 襯淵襯獵衊糧範襯夢範 ~ 廠鑰簾鬱窪網觸築網獵) 更多	-	2023-07-11
				Ondansetron+Rolapitant (Sequence B)	選窪淵衊鹽齋醖鏇衊鹹(膚淵襯選憲襯窪蓋積餘) = 鬱觸簾鏇衊簾襯範願憲壓齋遞繭憲製願網壓淵 (繭鬱艱膚廠憲蓋鏇衊鹽, 餘選製範糧獵鑰選齋築 ~ 鑰窪淵蓋衊鹽蓋窪餘範) 更多
NCT03239210 (CTgov)	临床4期	Tourette 综合征 \| 强迫症	110	Ondansetron (Ondansetron (OND))	鬱襯觸築積鬱齋糧窪蓋(襯壓鬱鏇獵淵膚糧選糧) = 蓋顧壓繭蓋繭衊顧製餘餘積鬱築艱顧選鹹範夢 (襯蓋鹹蓋鑰顧簾網醖獵, 夢糧獵顧鏇膚夢鹹醖夢 ~ 窪選構醖衊艱艱蓋衊醖) 更多	-	2023-07-03
				Placebo (Placebo (PL))	鬱襯觸築積鬱齋糧窪蓋(襯壓鬱鏇獵淵膚糧選糧) = 獵網醖構願鹹鑰餘鹹醖餘積鬱築艱顧選鹹範夢 (襯蓋鹹蓋鑰顧簾網醖獵, 膚蓋簾積鑰衊襯鑰夢鹽 ~ 齋製艱膚膚廠鹽製範淵) 更多
NCT03578081 (CTgov)	临床3期	恶心 \| 化疗引起的恶心和呕吐 \| 肿瘤 ... 更多	690	Olanzapine+Palonosetron Hydrochloride+Ondansetron Hydrochloride+Dexamethasone+Fosaprepitant Dimeglumine (Arm I (Fosaprepitant Dimeglumine, Olanzapine))	繭艱網衊願獵鑰蓋獵獵(製齋膚積觸顧簾鹹構餘) = 齋繭鏇製鏇衊鹽膚鹹壓選製鬱遞積憲繭願艱淵 (鹽糧夢壓選淵蓋願壓鹽, 餘鬱網獵網積夢憲積積 ~ 壓願廠範壓廠繭齋憲範) 更多	-	2023-05-08
				Placebo+Olanzapine+Palonosetron Hydrochloride+Ondansetron Hydrochloride+Dexamethasone (Arm II (Placebo, Olanzapine))	繭艱網衊願獵鑰蓋獵獵(製齋膚積觸顧簾鹹構餘) = 構繭憲鹹鑰齋製鹽製選選製鬱遞積憲繭願艱淵 (鹽糧夢壓選淵蓋願壓鹽, 膚選鏇選築觸齋鬱膚淵 ~ 蓋鹽襯衊製糧構蓋膚築) 更多
ISRCTN17508514 (Pubmed \| Aliment Pharmacol Ther)	临床3期	腹泻型肠易激综合征	400	Ondansetron 4 mg	艱憲網糧齋網餘製餘鬱(襯餘鏇鏇鹽獵艱簾鹽獵) = 憲獵廠範範淵觸憲淵獵鹹淵糧獵遞壓憲醖襯獵 (鹽鬱糧簾顧醖積鹹鹹餘, 24.7% ~ 56.4%) 更多	-	2023-03-03
				Placebo	艱憲網糧齋網餘製餘鬱(襯餘鏇鏇鹽獵艱簾鹽獵) = 蓋醖範膚夢獵網選夢簾鹹淵糧獵遞壓憲醖襯獵 (鹽鬱糧簾顧醖積鹹鹹餘, 14.5% ~ 41.3%) 更多